SAN FRANCISCO (Legal Newsline) - A new class action lawsuit alleges a cold sore treatment doesn't work as quickly as its manufacturer would have customers believe.
Plaintiff Jasmine Smith, through attorneys at Bursor & Fisher, filed the case Dec. 3 in U.S. District Court for the Northern District of California against GlaxoSmithKline, which makes Abreva cold sore treatment cream.
"Defendants represent that Abreva can heal a cold sore in 2 1/2 days, but it does not," the lawsuit says. "Defendants further represent that '(n)othing heals a cold sore faster,' despite readily available alternatives that do purport to heal cold sores faster."
These marketing claims exceed the scope of Abreva's approval by the Food and Drug Administration, the suit says.
Smith said her cold sore did not heal in the time period set out in Abreva's disclaimers.